- **Title:** Real world external validation of metabolic gestational age assessment in Kenya
-
- 3 Steven Hawken^{1,7}
- Victoria Ward²
- 5 A. Brianne Bota¹
- Monica Lamoureux³
- 7 Robin Ducharme¹
- 8 Lindsay A. Wilson¹
- Nancy Otieno⁴
- Stephen Munga⁴
- Bryan O. Nyawanda⁴
- 12 Raphael Atito⁴
- 13 Pranesh Chakraborty^{3,5}
- 14 Gary L. Darmstadt^{2*}
- 15 Kumanan Wilson^{1,6,7,8*}
-
- ¹Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
- ²Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford CA, USA
- ³Newborn Screening Ontario, Children's Hospital of Eastern Ontario, Ottawa, Canada
- ⁴Kenya Medical Research Institute (KEMRI), Center for Global Health Research, Kisumu, Kenya
- ⁵Department of Pediatrics, University of Ottawa, Ottawa, Canada
- ⁶Department of Medicine, University of Ottawa, Ottawa, Canada
- ⁷School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
- ⁸Bruyère Research Institute, Ottawa, Canada
-
- *Co-senior authors; these authors contributed equally to this project.
- **Corresponding author:** Kumanan Wilson [\(kwilson@ohri.ca](mailto:kwilson@ohri.ca))
-
-

Keywords: gestational age algorithm, newborn screening, dried blood spots, LMIC, Kenya, KEMRI

-
- **Word Count:** 2360
-

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

-
- Using data from Ontario Canada, we previously developed machine learning-based algorithms incorporating newborn screening metabolites to estimate gestational age (GA). The objective of this study was to evaluate the use of these algorithms in a population of infants born in Siaya county, Kenya. Cord and heel prick samples were collected from newborns in Kenya and metabolic analysis was carried out by Newborn Screening Ontario in Ottawa, Canada. Postnatal GA estimation models were developed with data from Ontario with multivariable linear regression using ELASTIC NET regularization. Model performance was evaluated by applying the models to the data collected from Kenya and comparing model-derived estimates of GA to reference estimates from early pregnancy ultrasound. Heel prick samples were collected from 1,039 newborns from Kenya. Of these, 8.9% were born preterm and 8.5% were small for GA. Cord blood samples were also collected from 1,012 newborns. In data 47 from heel prick samples, our best-performing model estimated GA within 9.5 days overall of reference GA 48 [mean absolute error (MAE) 1.35 (95% CI 1.27, 1.43)]. In preterm infants and those small for GA, MAE was 2.62 (2.28, 2.99) and 1.81 (1.57, 2.07) weeks, respectively. In data from cord blood, model accuracy slightly decreased overall (MAE 1.44 (95% CI 1.36, 1.53)). Accuracy was not impacted by maternal HIV status and improved when the dating ultrasound occurred between 9 and 13 weeks of gestation, in both heel prick and cord blood data (overall MAE 1.04 (95% CI 0.87, 1.22) and 1.08 (95% CI 0.90, 1.27), respectively). Compared to internal validation performance using Ontario data and to our previously published external validations, model performance was diminished in the Kenya cohort, suggesting that reference ultrasound timing is an important factor in model performance. Our study highlights the challenges in reliably estimating GA in low resource settings, even those with access to dating ultrasound, given that the timing of dating ultrasound is critical to develop algorithms for accurate estimation of GA based on metabolic analysis of blood obtained at birth.
-
-
-
-

Introduction

 The need for novel, non-invasive methods to accurately estimate gestational age (GA) in low resource settings has been identified by the World Health Organization as a priority area for improving global estimation of the burden of preterm birth at < 37 completed weeks of gestation. Preterm birth as well as being born small (small for gestational age; SGA = lowest ten centiles of birthweight given gestational age) are leading causes of infant mortality and morbidity, particularly in low- and middle-income countries (LMIC).1,2 Furthermore, medical needs and developmental milestones differ between term, preterm and SGA infants and thus, accurately identifying at-risk infants at birth is important in informing their postnatal care and supportive resources. Although the use of first-trimester ultrasound has improved our ability to estimate 72 GA³, it is not widely available in all low resource settings and its implementation poses significant obstacles, 73 including cost, training, equipment maintenance and lack of standardization.⁴ In low resource settings without access to prenatal ultrasound, GA estimates are often made based on last menstrual period, the accuracy of which may be affected by memory recall as well as irregular menses and maternal malnutrition.5,6 Commonly used postnatal examination methods for GA dating of infants (e.g., Dubowitz or Ballard score) also have limitations in terms of their accuracy – particularly in preterm and growth-restricted infants – and their utility is further limited by challenges with feasibility and high inter-user variability.⁷ Given the limitations associated with existing GA dating methods, numerous research groups are testing new 81 ways to accurately estimate GA.^{8–11} We have developed novel machine learning-based algorithms that use

- 82 newborn screening metabolites and clinical and demographic covariates to estimate GA.^{12,13} These
- algorithms were originally developed and internally validated in a large cohort of newborns in Ontario,
- 84 Canada.^{14,15} Refinements to the algorithms incorporated machine learning and improved the accuracy of
- 85 gestational age estimations.^{12,16} Here we evaluate the use of these algorithms in a population of infants born in Siaya County, Kenya.
-

Methods

Ethics

- This study was approved by the Ottawa Health Sciences Network Research Ethics Board (20180330-01H),
- Children's Hospital of Eastern Ontario Research Ethics Board (18/58X), the Stanford University School of
- Medicine Institutional Review Board (44656) and the Kenya Medical Research Institute (KEMRI) Scientific
- 93 and Ethics Review Unit (SSC 2880).
-

Study setting

- A detailed study protocol has previously been published which describes the study sites and provides further
- 97 details on sample collection and processing.¹⁷ The Kenya study site is located in Kisumu at the KEMRI
- Centre for Global Health Research, with field sites located in Siaya County, where a maternal-infant
- demographic surveillance program followed a prospective cohort of pregnant women and their infants in two
- community hospitals: Siaya County Referral Hospital (SCRH) and Bondo sub-County Hospital (BSCH).

Eligible participants were pregnant women between the ages of 15-49 years, residing within a 10 km radius

of the research facility, willing to deliver in the research hospital, and not planning to relocate within 1 year

of enrollment into the surveillance program. Participants were enrolled at their first antenatal care visit

(ANC-1), which typically occurred prior to 20 weeks' gestation. Participants underwent an early pregnancy

ultrasound as early as possible and were offered treatment for common illnesses, including malaria, urinary

- tract infections, and sexually transmitted infections. A small portion of infants were born at home and
- evaluated within 72 hours of delivery.
-

Consent

 Informed written parental consent was obtained prior to study enrollment. All liveborn infants of enrolled mothers were eligible for inclusion.

Collection of newborn screening specimens

 Cord blood samples were collected via syringe within 30 minutes of delivery of the placenta. Four to five drops of blood from the syringe were applied to filter paper within pre-printed circles. Heel prick samples were collected from newborns ideally between 24-72 hours after birth, or prior to discharge if the newborn was released from the hospital within 24 hours of delivery. The newborn's heel was warmed prior to skin puncture to promote blood flow. The puncture site was cleaned and air-dried and a sterile lancet was used to puncture the lateral plantar aspect of the newborn's heel. The first drop of blood was wiped away and 4-5 drops of blood were applied within pre-printed circles of a second filter paper.

 Heel and cord dried blood spot (DBS) cards were dried and stored at ambient temperature and shipped weekly to the Newborn Screening Ontario (NSO) laboratory at the Children's Hospital of Eastern Ontario in Ottawa, Canada for analysis, along with clinical and demographic information required for clinical interpretation of metabolic profiles and for metabolic GA estimation models. This information included infant sex, birthweight (in grams), multiple birth status, GA (in weeks + days), date of birth, and timing of sample collection.

Newborn screening analysis

The newborn screening analysis process has been described in detail previously.¹⁷ Dried blood spot samples

were analyzed for the following metabolites: hemoglobin profiles, 17-hydroxyprogesterone (17-OHP),

thyroid stimulating hormone (TSH), immunoreactive trypsinogen (IRT), a panel of 12 amino acids and

31 acylcarnitines, t-cell receptor excision circles (TREC), biotinidase activity, and galactose-1-

phosphate uridylyltransferase activity (Table 1). Real-time screening for three conditions [congenital

hypothyroidism (CH), hemoglobinopathies, and medium-chain acyl-CoA dehydrogenase deficiency

(MCADD)] occurred during this study. These conditions were deemed to be high priority for reporting and

- were treatable at the local collection sites. Results of screening for congenital metabolic conditions will be
- published elsewhere.

- 139
- 140 *Data preparation and statistical analysis*
- 141 All analyses were conducted using SAS 9.4 and R 3.3.2. Data preparation steps, including standardization
- 142 and log transformations are detailed in S1 Appendix.
- 143
- 144 Analytes were included as candidate predictors in GA estimation models based on their routine measurement
- 145 as part of Ontario's expanded newborn screening program, including hemoglobin profiles, amino acids,
- 146 acylcarnitines, hormone and endocrine markers, enzymes and co-enzymes (Table 1). Newborn GA was
- 147 estimated from models derived using multivariable regression coupled with elastic net regularization and
- 148 including the following covariates:
- 149 1. Model 1: Birth weight, sex, multiple birth status and pairwise interactions.
- 150 2. Model 2: Birth weight, sex, multiple birth status and newborn screening analytes and pairwise 151 interactions.
- 152

153 **Table 1. Newborn screening analytes included in predictive models**

154

 Models were trained and internally validated in independent training and validation/test cohorts of infants from Ontario, Canada (S1 Appendix). These pretrained models were then applied to the data for infants from the external cohorts to estimate GA. To evaluate model accuracy, GA estimates were compared to the ultrasound reference GA for each infant, and the residual error calculated. Different metrics were calculated to estimate model uncertainty, including mean square error (MSE), standard error of estimation [also known as root mean square error (RMSE)], and mean absolute error (MAE), which is the average of the absolute value of the residual across all subjects (or subsets of subjects). Additionally, we calculated the proportion of 162 model-derived estimates that fell within ± 1 week of reference GA. MAE was the main performance metric used to evaluate model accuracy, but multiple metrics were calculated and reported to facilitate comparisons

 to other models developed by our group and others. Model-derived frequency of preterm birth will be compared to the observed prevalence of preterm birth.

-
-

Results

- 1,039 newborns had heel prick samples available, as well as clinical and demographic data including
- ultrasound-derived reference GA. Of these, 92 infants (8.9%) were preterm and 88 (8.5%) were SGA (Table
- 2). 1,012 newborns (97.4%) also had a cord blood sample collected. It should be noted that the Ontario
- cohort in which the models were developed and internally validated had a lower preterm birth prevalence of
- 5.6% and SGA prevalence of 3.9% (Table 2).
-

Model-based GA estimation for heel prick samples

- Overall, Model 1, which included only readily available clinical covariates (sex, birthweight and multiple
- birth status) estimated GA within 10.5 days on average, with a MAE of 1.5 (95% CI 1.41, 1.58) weeks.
- 178 58.5% of model estimates were within ± 1 week of reference GA. For preterm births, Model 1 MAE was
- 179 2.64 (95% CI 2.30,3.01) weeks and only 24.1% of estimates were within ± 1 week of reference GA. In SGA
- 180 newborns, MAE was 3.13 (95% CI 2.85, 3.38) weeks and 3.4% of estimates were within ± 1 week of
- reference GA (Table 2). Model 2, which included clinical covariates plus analytes, estimated GA within 9.5
- 182 days overall, with a MAE of 1.35 (95% CI 1.27, 1.43) weeks, and 64.1% of estimates were within ± 1 week
- of reference GA. In preterm infants, MAE was 2.62 (95% CI 2.28, 2.99) weeks and in SGA infants the MAE was 1.81 (95% CI 1.57, 2.07) weeks (Table 3).
-

 The performance of Models 1 and 2 did not appear to be affected by the HIV status of the mother. Results for subjects with HIV-positive mothers (n=197) were almost identical to model performance for infants of HIV-188 negative mothers (n=842) (Table 4).

-
- *Model-based GA estimation for cord-blood samples*
- Model 1 demonstrated nearly identical performance in cord blood samples compared to heel prick samples,
- as analytes were not covariates in Model 1, and the heel and cord blood cohorts were almost entirely
- comprised of the same infants. Overall, in the cord blood cohort, Model 2 had a MAE of 1.44 (95% CI 1.36,
- 1.53) weeks. In preterm infants, Model 2 had a MAE of 2.79 (95% CI 2.46, 3.12) weeks and in SGA infants
- the MAE was 2.06 (95% CI 1.76, 2.36) weeks (Table 2). Like the heel prick results, model performance was
- not sensitive to the HIV status of the mother (Table 5 and Table 6).
-

Model-based GA estimation using reference GA derived from ultrasounds within recommended window

There was significant variation in the timing of gestational dating ultrasound, despite best efforts to conduct

- the ultrasound as early as possible. Reference GA for 28 newborns (2.7%) was derived from ultrasound
- 201 conducted before 9 weeks' gestation, and 889 (85.6%) had reference GA based on an ultrasound later than

202 13 weeks' gestation. Only 120 newborns (11.5%) had reference GA based on an ultrasound conducted within

9-13 weeks' gestation (Table 4). When evaluated in these 120 newborns, model performance was markedly

better, with Model 2 having a MAE of 1.04 (95% CI 0.87, 1.22) weeks overall and a MAE of 2.56 (95% CI

1.50, 4.00) and 1.07 (95% CI 0.46, 1.70) weeks in preterm and SGA infants, respectively (Table 5).

207 Similar to the heel prick results, Model 2 for cord blood specimens performed markedly better when only samples with reference GA ascertained between 9 and 13 weeks of gestation were included [overall MAE 1.08 (95% CI 0.90, 1.27) weeks] (Table 5).

Discussion

 We externally validated the performance of a postnatal GA dating algorithm developed and validated in a cohort of infants in Ontario, Canada in a prospective birth cohort in Siaya County Kenya, a lower-middle- income sub-Saharan African country. Heel prick and umbilical cord blood samples were collected shortly after birth, and ultrasound was used to provide a reference GA for each infant. Overall, model performance was worse in the Kenya birth cohort for Model 1 and Model 2 compared to internally validated model 217 performance in Ontario, and in comparison to previously published external validations of metabolic GA 218 algorithms.^{12,13} The heterogeneity of reference ultrasound timing was an important contributor to diminished model performance, as only 120 out of 1,039 participants had reference ultrasound completed between 9 and 220 13 weeks of gestation. Model performance was markedly better in participants with reference GA ascertained inside compared to outside the recommended window. For example, Model 2 had an overall MAE of 1.04 weeks among infants with reference GA between 9 and 13 weeks, compared to MAEs of 1.48 (<9 weeks), 1.34 (14-20 weeks) and 1.43 (>20 weeks) weeks for those with dating ultrasounds earlier and later than the recommended window. A similar pattern was seen for Model 1 and Model 2 in heel and cord samples both overall and in preterm and SGA newborns. Our study highlights the challenges in reliably 226 estimating GA in low resource settings, even in those with access to dating ultrasound, given that the timing 227 of dating ultrasound is critical to accurate estimations of GA.^{3,18} Indeed, most pregnant women in Kenya 228 access ANC for the first time in the second trimester¹⁹. These challenges further underscore the need for novel, reliable GA estimation methods that can be adopted in LMICs.

 Given the significant barriers to obtaining an early dating ultrasound, the metabolic GA approach may be a 232 more feasible and accurate approach to GA dating than dating ultrasound when the timing of the latter is variable. Our study also demonstrated the utility of cord blood samples, which could further strengthen the feasibility of our approach in low resource settings. Cord blood samples are obtained shortly after birth and remove the burden of sample collection before discharge, do not cause any discomfort to the newborn and may be more readily accepted by parents who are not accustomed to the heel prick procedure. Given the 237 higher prevalence of HIV in our patient population, our results also provide reassurance that HIV positive status does not appear to impact performance of algorithms based only on clinical measurements (Model 1) or those including metabolic markers measured in heel prick or cord blood (Model 2).

 The major limitation of our study was the small number of GA ultrasounds conducted during the optimal reference time-period. Therefore, a gold standard for reliable comparison with accurate true GA was not possible for a large percentage of the sample. Strengths of the study include the real-world approach to evaluating the algorithm, allowing us to assess not only model performance but the feasibility of this GA estimation approach as well.

 Our study demonstrated that, despite being conducted within a prospective pregnancy cohort with a well-248 defined protocol in a controlled research setting, there were still challenges in obtaining a true reference GA measurement. The results of this evaluation suggest that postnatal GA estimation algorithms such as the ones we have developed are both feasible and accurate, and previous analyses have indicated that GA estimation 251 algorithm approaches are also potentially cost-effective.²⁰ Therefore, we believe that GA estimation algorithms based on metabolic analysis of heel prick or cord blood DBS may be able to serve an important

role in both individual infant estimates of GA and population level estimations of preterm birth rates.

- Algorithm-based GA estimates have potential even in settings where early ultrasound is available, given the
- substantial heterogeneity in timing of reference GA ultrasound in our population, a factor that may
- compromise the accuracy of estimates based on ultrasound alone. Given these findings, we believe that GA
- estimation algorithms may serve an important role in providing both individual estimates of GA and
- population-level estimates of preterm birth.
-

Acknowledgements

This research was supported by the Bill & Melinda Gates Foundation (OHRI: OPP1184574; Stanford:

OPP1182996).

Contributions

- Conceptualization KW, GLD, VW, PC, NO; Data Curation BON, RA, ABB, RD, ML; Formal Analysis SH;
- Funding Acquisition KW, GLD, VW; Investigation NO, SM, BON, RA, ABB, LM, LAW; Methodology
- VW, KW, GLD, PC, ML, LAW; Project Administration ABB, ML, LM, VW, NO, RA; Resources NO, LM,
- ML, VW, RA BON; Software SH; Supervision KW, GLD, VW, NO; Writing -original Draft preparation-
- ABB, SH, RD; Writing-review and editing- all authors reviewed and edited the manuscript.
-

References

- 1. World Health Organization. *Born Too Soon: The Global Action Report on Preterm Birth*.; 2012. doi:http://whqlibdoc.who.int/publications/2012/9789241503433_eng.pdf
- 275 2. Blencowe H, Cousens S, Chou D, et al. Born Too Soon : The global epidemiology of 15 million preterm births Understanding the data Preterm birth -- what is it ? Defining preterm birth. 2013;10(Suppl 1):1-13. doi:10.1186/1742
- 5. Hoffman CS, Messer LC, Mendola P, Savitz DA, Herring AH, Hartmann KE. Comparison of gestational age at birth based on last menstrual period and ultrasound during the first

- 280 trimester. *Paediatr Perinat Epidemiol*. 2008;22(6):587-596. doi:10.1111/j.1365- 281 3016.2008.00965.x
- 282 19. Nyiro JU, Bukusi E, Mwaengo D, et al. Implications of gestational age at antenatal care 283 attendance on the successful implementation of a maternal respiratory syncytial virus (RSV) 284 vaccine program in coastal Kenya. *BMC Public Health*. 2020;20(1). doi:10.1186/S12889- 285 020-09841-9
- 286 20. Coyle K, Quan AML, Wilson LA, et al. Cost-effectiveness of a gestational age metabolic 287 algorithm for preterm and small-for-gestational-age classification. *Am J Obstet Gynecol* 288 *MFM*. 2021;3(1):100279. doi:10.1016/j.ajogmf.2020.100279
- 289
- 290
- 291

292 **Table 2. Cohort Characteristics**

293 SGA, small for gestational age (lowest 10 and 3 centiles within gestational age and sex strata,

294 calculated in the Ontario cohort using Intergrowth-21 centiles and applied uniformly in the Ontario, 295 China and Philippines cohorts)

296 297

Models	Kenya Heel Prick Samples			Kenya Cord Blood Samples		
	Overall, $N=1,039$	Preterm, N=93	SGA, $N=88$	Overall, $N=1.012$	Preterm, N=91	SGA, $N = 87$
Model 1: Sex and birth weight						
MAE (CI) RMSE (CI) $\frac{9}{6}$ +/-1 wk (CI)	58.5 (55.3, 61.6) 24.1 (14.5, 34.1)	1.50 $(1.41, 1.58)$ 2.64 $(2.30, 3.01)$ $2.02(1.91, 2.13)$ 3.09 (2.75, 3.45)	3.13(2.85, 3.38) 3.39(3.06, 3.70) 3.4(0.0, 7.7)	1.51(1.42, 1.59) 2.04(1.94, 2.16) 58.4 (55.4, 61.6)	(2.70 (2.39, 3.04)) 3.14(2.84, 3.49) 23.4(13.7, 32.0)	3.17(2.91, 3.46) 3.43(3.10, 3.77) 3.6(0.0, 8.3)
Model 2: Sex, Birth weight and analytes						
MAE (CI) RMSE (CI) $\frac{1}{6}$ +/-1 wk (CI)	1.35(1.27, 1.43)	2.62(2.28, 2.99) 1.83 $(1.72, 1.94)$ 3.09 $(2.74, 3.48)$ 64.1 (61.1, 67.2) 29.4 (20.2, 38.9)	1.81(1.57, 2.07) 2.18(1.91, 2.46) 46.9 (35.8, 57.3)	1.44(1.36, 1.53) 1.95(1.85, 2.06) 61.2 (58.3, 63.9)	2.79(2.46, 3.12) 3.19(2.85, 3.57) 21.1(11.8, 29.3)	2.06(1.76, 2.36) $\vert 2.41 \, (2.13, 2.69) \vert$ 33.2 (23.0, 44.6)

Table 3. Summary of model performance to estimate gestational age in samples from Kenya

MAE: Mean absolute error; RMSE: Root mean square error; SGA: small for gestational age Data are presented as the mean and 2.5th and 97.5th bootstrap percentiles for MAE, RMSE and the percentage of model estimates within 1 and 2 weeks of ultrasound GA for 1000 bootstrap samples generated from each cohort.

Table 4. Summary of model performance to estimate gestational age in heel prick samples according to HIV status and timing of GA dating ultrasound

MAE: Mean absolute error; RMSE: Root mean square error; SGA: small for gestational age Data are presented as the mean and 2.5th and 97.5th bootstrap percentiles for MAE, RMSE and the percentage of model estimates within 1 and 2 weeks of ultrasound GA for 1000 bootstrap samples generated from each cohort.

Table 5. Summary of model performance in Cord Blood Samples According to HIV Status and Timing of GA Dating Ultrasound (US)

MAE: Mean absolute error; RMSE: Root mean square error; SGA: small for gestational age Data are presented as the mean and 2.5th and 97.5th bootstrap percentiles for MAE, RMSE and the percentage of model estimates within 1 and 2 weeks of ultrasound GA for 1000 bootstrap samples generated from each cohort.

MAE: Mean absolute error; RMSE: Root mean square error; SGA: small for gestational age Data are presented as the mean and 2.5th and 97.5th bootstrap percentiles for MAE, RMSE and the percentage of model estimates within 1 and 2 weeks of ultrasound GA for 1000 bootstrap samples generated from each cohort.